Geometric Mean Fold Rise of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Geometric Mean Titer of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Proportion of Adverse Event Of Special Interest (AESI);Proportion of clinically significant changes in clinical safety laboratory parameters;Proportion of immediate adverse events (AE);Proportion of Medically-Attended Adverse Events (MAAE);Proportion of participants achieving seroresponse of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Proportion of SAE;Proportion of solicited local and systemic AE;Proportion of unsolicited AE

Geometric Mean Fold Rise of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Geometric Mean Titer of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Proportion of Adverse Event Of Special Interest (AESI);Proportion of clinically significant changes in clinical safety laboratory parameters;Proportion of immediate adverse events (AE);Proportion of Medically-Attended Adverse Events (MAAE);Proportion of participants achieving seroresponse of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody);Proportion of SAE;Proportion of solicited local and systemic AE;Proportion of unsolicited AE